These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 12040527)

  • 1. Increasing treatment options in indolent non-Hodgkin's lymphoma.
    Solal-Céligny P
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):2-6. PubMed ID: 12040527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor [corrected].
    Kimby E
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):7-10. PubMed ID: 12040528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatment approaches to indolent non-Hodgkin's lymphoma.
    Seymour JF
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):27-32. PubMed ID: 15042532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma.
    Brandt L; Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):213-23. PubMed ID: 11441933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab therapy for indolent non-Hodgkin's lymphoma.
    Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab: an innovative therapy for non-Hodgkin's lymphoma.
    Wood AM
    Am J Health Syst Pharm; 2001 Feb; 58(3):215-29; quiz 230-2. PubMed ID: 11217177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.
    Davis TA; Maloney DG; Grillo-López AJ; White CA; Williams ME; Weiner GJ; Dowden S; Levy R
    Clin Cancer Res; 2000 Jul; 6(7):2644-52. PubMed ID: 10914705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in indolent lymphomas.
    Sousou T; Friedberg J
    Semin Hematol; 2010 Apr; 47(2):133-42. PubMed ID: 20350660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
    Fanale MA; Younes A
    Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
    Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma.
    Economopoulos T; Fountzilas G; Pavlidis N; Kalantzis D; Papageorgiou E; Christodoulou C; Hamilos G; Nicolaides C; Dimopoulos M
    Hematol J; 2003; 4(2):110-5. PubMed ID: 12750729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Cvetković RS; Perry CM
    Drugs; 2006; 66(6):791-820. PubMed ID: 16706552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunochemotherapy in indolent non-Hodgkin's lymphoma.
    Czuczman MS
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):11-7. PubMed ID: 12040529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial.
    Hainsworth JD
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):25-9. PubMed ID: 11842385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.
    Hainsworth JD
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Debate on the conservative and aggressive treatment options for the optimal management of indolent non-Hodgkin's lymphoma.
    Imrie KR; Linch DC; Czuczman MS
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S19-24. PubMed ID: 12710587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of follicular non-Hodgkin's lymphoma.
    Maloney DG
    Curr Hematol Rep; 2005 Jan; 4(1):39-45. PubMed ID: 15610658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.